alexa PTEN Status And Akt Phosphorylation: Implications For The Rituximab-resistance In B-cell Lymphoma
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

7th World Hematologists Congress
May 08-09, 2017 Barcelona, Spain

Jingjing Wu
First Affiliated Hospital of Zhengzhou University, China
Posters & Accepted Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864-C1-023
Rituximab has been widely used in clinical practice for the treatment of B-cell malignancies, but the majority of patients retreated with rituximab will eventually relapse with variable degrees of resistant disease. There is an urgent need to explore the mechanisms of resistance to rituximab in non–Hodgkin’s lymphoma (NHL), and to develop therapeutic strategies to overcome resistance. Herein, we successfully set up three types of rituximab-resistant B lymphoma cell lines with different malignancy grade, and demonstrate that phosphatase and tensin homolog (PTEN) is low expressed in the rituximab-resistant cell lines. Furthermore, we report that reduced PTEN expression correlated with resistance to rituximab and inhibited tumor cell apoptosis through activation of Akt phosphorylation. Restoration of PTEN expression resulted in re-sensitization of resistant cells to rituximab through modulation of apoptosis by suppressing the p-Akt in the PI3K/Akt signaling pathway. Overall, our findings demonstrate a novel mechanism of rituximab-resistance by the involvement of PTEN status and Akt phosphorylation in three different types of rituximab-resistant B lymphoma cell lines, which may be new predictive markers for response to rituximab and provide new insights for reversing rituximab resistance in B-cell lymphoma.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version